Medtronic receives FDA approval for BrainSense Adaptive DBS technology

FHS
March 3, 2025
5:06 am

For the one million people diagnosed with Parkinson’s disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI).

Trial investigates efficacy of online supervised group mental and physical rehabilitation program for long COVID patients

Researchers evaluated the efficacy of an online supervised group mental and physical rehabilitation program in adults with long COVID.

February 12, 2024

Advances in bladder cancer treatments offer hope for curative care

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an

November 14, 2024

US and UK experience high levels of working-age mortality compared to high-income countries

A new study by researchers at the Leverhulme Centre for Demographic Science (LCDS) and Princeton University reveals that US working-age adults are dying at higher

March 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.